1. Krammer, F. The human antibody response to influenza A virus infection and vaccination. Nat. Rev. Immunol. 19, 383–397 (2019).
2. Neuberger, M. S. & Rajewsky, K. Activation of mouse complement by monoclonal mouse antibodies. Eur. J. Immunol. 11, 1012–1016 (1981).
3. Gessner, J. E., Heiken, H., Tamm, A. & Schmidt, R. E. The IgG Fc receptor family. Ann. Hematol. 76, 231–248 (1998).
4. Heusser, C. H., Anderson, C. L. & Grey, H. M. Receptors for IgG: subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line. J. Exp. Med. 145, 1316–1327 (1977).
5. Huber, V. C., Lynch, J. M., Bucher, D. J., Le, J. & Metzger, D. W. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J. Immunol. Baltim. Md 1950 166, 7381–7388 (2001).
6. Kipps, T. J., Parham, P., Punt, J. & Herzenberg, L. A. Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies. J. Exp. Med. 161, 1–17 (1985).
7. Takai, T., Li, M., Sylvestre, D., Clynes, R. & Ravetch, J. V. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 76, 519–529 (1994).
8. Unkeless, J. C. & Eisen, H. N. Binding of monomeric immunoglobulins to Fc receptors of mouse macrophages. J. Exp. Med. 142, 1520–1533 (1975).
9. Nimmerjahn, F., Bruhns, P., Horiuchi, K. & Ravetch, J. V. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23, 41–51 (2005).
10. Nimmerjahn, F. & Ravetch, J. V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310, 1510–1512 (2005).
11. Huber, V. C. et al. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin. Vaccine Immunol. CVI 13, 981–990 (2006).
12. Hannoun, C. The evolving history of influenza viruses and influenza vaccines. Expert Rev. Vaccines 12, 1085–1094 (2013).
13. Nicholson, K. G., Wood, J. M. & Zambon, M. Influenza. Lancet Lond. Engl. 362, 1733–1745 (2003).
14. Cox, R. J., Brokstad, K. A. & Ogra, P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 59, 1–15 (2004).
15. Hovden, A.-O., Cox, R. J., Madhun, A. & Haaheim, L. R. Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice. Scand. J. Immunol. 62, 342–352 (2005).
16. Coutelier, J. P., van der Logt, J. T., Heessen, F. W., Warnier, G. & Van Snick, J. IgG2a restriction of murine antibodies elicited by viral infections. J. Exp. Med. 165, 64–69 (1987).
17. Coutelier, J. P., van der Logt, J. T., Heessen, F. W., Vink, A. & van Snick, J. Virally induced modulation of murine IgG antibody subclasses. J. Exp. Med. 168, 2373–2378 (1988).
18. Hovden, A.-O., Cox, R. J. & Haaheim, L. R. Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scand. J. Immunol. 62, 36–44 (2005).
19. Moran, T. M., Park, H., Fernandez-Sesma, A. & Schulman, J. L. Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection. J. Infect. Dis. 180, 579–585 (1999).
20. Schlesinger, J. J. & Chapman, S. Neutralizing F(ab’)2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis. J. Gen. Virol. 76 ( Pt 1), 217–220 (1995).
21. Snapper, C. M. & Paul, W. E. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236, 944–947 (1987).
22. Barackman, J. D., Ott, G. & O’Hagan, D. T. Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and serum immunity which is stronger than that with traditional intramuscular immunization. Infect. Immun. 67, 4276–4279 (1999).
23. Hovden, A.-O., Cox, R. J., Madhun, A. & Haaheim, L. R. Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice. Scand. J. Immunol. 62, 342–352 (2005).
24. Visciano, M. L., Tagliamonte, M., Tornesello, M. L., Buonaguro, F. M. & Buonaguro, L. Effects of adjuvants on IgG subclasses elicited by virus-like particles. J. Transl. Med. 10, 4 (2012).
25. Patel, J. R. et al. ATPase-driven oligomerization of RIG-I on RNA allows optimal activation of type-I interferon. EMBO Rep. 14, 780–787 (2013).
26. Jangra, S. et al. Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Modified Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine. BioRxiv Prepr. Serv. Biol. 2020.10.23.344085 (2020) doi:10.1101/2020.10.23.344085.
27. Martínez-Gil, L. et al. A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant. J. Virol. 87, 1290–1300 (2013).
28. De Coen, R. et al. pH-Degradable Mannosylated Nanogels for Dendritic Cell Targeting. Biomacromolecules 17, 2479–2488 (2016).
29. Pulendran, B., S Arunachalam, P. & O’Hagan, D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454–475 (2021).
30. Snapper, C. M. & Paul, W. E. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236, 944–947 (1987).
31. Choi, A., García-Sastre, A. & Schotsaert, M. Host immune response-inspired development of the influenza vaccine. Ann. Allergy Asthma Immunol. Off. Publ. Am. Coll. Allergy Asthma Immunol. 125, 28–35 (2020).
32. Lopez, C. E. & Legge, K. L. Influenza A Virus Vaccination: Immunity, Protection, and Recent Advances Toward A Universal Vaccine. Vaccines 8, E434 (2020).
33. Boudreau, C. M. & Alter, G. Extra-Neutralizing FcR-Mediated Antibody Functions for a Universal Influenza Vaccine. Front. Immunol. 10, 440 (2019).
34. Keeler, S. P. & Fox, J. M. Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections. Viruses 13, 1037 (2021).
35. Nimmerjahn, F. et al. FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 107, 19396–19401 (2010).
36. Chromikova, V. et al. Activity of human serum antibodies in an influenza virus hemagglutinin stalk-based ADCC reporter assay correlates with activity in a CD107a degranulation assay. Vaccine 38, 1953–1961 (2020).
37. Uccellini, M. B., Aslam, S., Liu, S. T. H., Alam, F. & García-Sastre, A. Development of a Macrophage-Based ADCC Assay. Vaccines 9, 660 (2021).
38. Cyster, J. G. & Allen, C. D. C. B Cell Responses: Cell Interaction Dynamics and Decisions. Cell 177, 524–540 (2019).
39. Upasani, V., Rodenhuis-Zybert, I. & Cantaert, T. Antibody-independent functions of B cells during viral infections. PLoS Pathog. 17, e1009708 (2021).
40. Nakaya, H. I. et al. Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood. Proc. Natl. Acad. Sci. U. S. A. 113, 1853–1858 (2016).
41. Lapi, F. et al. Adjuvanted versus nonadjuvanted influenza vaccines and risk of hospitalizations for pneumonia and cerebro/cardiovascular events in the elderly. Expert Rev. Vaccines 18, 663–670 (2019).
42. Liang, Z. et al. Adjuvants for Coronavirus Vaccines. Front. Immunol. 11, 589833 (2020).
43. Feron, V. J. & Kruysse, A. Effects of exposure to acrolein vapor in hamsters simultaneously treated with benzo[a]pyrene or diethylnitrosamine. J. Toxicol. Environ. Health 3, 379–394 (1977).
44. Dekkers, G. et al. Affinity of human IgG subclasses to mouse Fc gamma receptors. mAbs 9, 767–773 (2017).
45. Braathen, R. et al. The Magnitude and IgG Subclass of Antibodies Elicited by Targeted DNA Vaccines Are Influenced by Specificity for APC Surface Molecules. ImmunoHorizons 2, 38–53 (2018).
46. Kalia, V., Sarkar, S., Gourley, T. S., Rouse, B. T. & Ahmed, R. Differentiation of memory B and T cells. Curr. Opin. Immunol. 18, 255–264 (2006).
47. Mosmann, T. R. & Sad, S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17, 138–146 (1996).
48. Snyder, J. M. et al. Humanized TLR7/8 expression drives proliferative multisystemic histiocytosis in C57BL/6 mice. PloS One 9, e107257 (2014).
49. Kugelberg, E. Innate immunity: Making mice more human the TLR8 way. Nat. Rev. Immunol. 14, 6 (2014).